Ash 2021 – Sangamo and Sanofi enter the sickle cell gene editing fray
SAR445136 could take on Crispr and Vertex’s CTX001, but plenty of other groups have the same idea.
Ash 2021 – Bluebird looks to revive Lentiglobin
Data in sickle cell disease look encouraging, but a filing is a way away.
Ash 2021 – Precision moves quickly to deal with allo disappointment
Like its two competitors Precision shows lack of durability with its allogeneic Car-T approach, but makes a quick move to next-gen assets.
Adicet scores the first hit for gamma-delta
Three of four lymphoma patients given ADI-001 go into remission, and Adicet soars 30%.
What Novartis could buy with its windfall
The group will get nearly $21bn for its Roche stake, and more if it sells Sandoz.
Global Blood takes on gene therapy
Proof-of-concept data at Ash should give clues about whether GBT021601 could be an oral functional cure for sickle cell disease.
Vertex goes small with Mammoth deal
Vertex strikes yet another gene editing deal, this time with the “ultra-small” Crispr specialist Mammoth.
